Can Diabetes Treatments Replace Patent Losses At Eli Lilly & Co?

Finally, things are looking up for Eli Lilly & Co.

Mar 5, 2014 at 6:30PM

The loss of Cymbalta, its no. 1 product, late last year and Evista this month are going to be tough on Eli Lilly and Co (NYSE:LLY). Rather than cutting back on R&D, the company has tried to spend its way out of trouble with little to show for it, until recently. The company's type 2 diabetes treatments look like they have a strong chance of winning approval. If they do, they'll run into fierce competition with existing drugs from Novo Nordisk (NYSE:NVO), AstraZeneca , GlaxoSmithKline (NYSE:GSK), and Johnson & Johnson (NYSE:JNJ). Let's take a look at Eli Lilly's diabetes lineup and see if it has a chance of grabbing some market share from these heavyweights.

Conducting trials and cutting deals
Unlike other big pharmaceutical companies facing major patent expirations, Lilly ramped up R&D spending in the face of shrinking revenue. Due to some rotten luck in late stage Alzheimer's and breast cancer trials, the plan hasn't worked out so well. The company's diabetes program might be able to turn things around with efforts from both the clinic and the conference room.

LLY Revenue (TTM) Chart

LLY Revenue (TTM) data by YCharts

In an increasingly austere environment, having an effective product isn't much good if patients can't get their insurance to cover most of the cost. Lilly has shown recently that it knows how to please the payers. To begin the new year, the largest pharmacy benefit manager in the US, Express Scripts, replaced Novo Nordisk's Novolog with Lilly's Humalog on its list of preferred products. That wasn't the only snub to the Danish drugmaker. Express Scripts also replaced daily injected Victoza with Byetta and its once-weekly version, Bydureon, from AstraZeneca.

Equally effective, more convenient
Discounts only go so far. Luckily, Lilly can tick the efficacy box as well. Recently the company announced some good news concerning its once-weekly, type 2 diabetes treatment, dulaglutide. This was the latest in a series of phase 3 trials comparing the glucagon-like peptide 1 (GLP-1) receptor agonist to potential competitors. The opponent was Novo Nordisk's highly successful Victoza.

Lilly didn't release detailed data from the 599-patient trial. The company stated that dulaglutide was just as effective at reducing blood sugar levels after 26 weeks. While being just as good might not seem terribly exciting, according to Lilly, it's the first GLP-1 agonist that can boast of non-inferiority to market leader Victoza. If approved, the treatment's once weekly dosing should go a long way to differentiate it from Novo Nordisk's treatment, which requires daily injections.

Not alone
Diabetes competition is fierce, even in the once-weekly GLP-1 space. If approved, Lilly's dulaglutide will be late to the game. AstraZeneca won FDA approval for its once-weekly GLP-1, Bydureon (exenatide) just over two years ago.

GlaxoSmithKline also has a GLP-1 agonist under review. The company submitted a biologics license application (BLA) to the FDA for albiglutide in January of last year. The agency has extended the Prescription Drug User Fee Act (PDUFA) goal date by a few months to April 2014.

Late last month, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for albiglutide. The EC typically follows the CHMP's opinion, so we can probably expect a European launch of albiglutide soon.

Dulaglutide is already under review in both major markets. So far the company hasn't given any indication that it might enter the market ahead of Glaxo. Hopefully, for Lilly the drug's efficacy advantage will be significant enough to impress both patients and physicians.

Another approach
Having a once weekly injection as effective as Victoza is a great selling point, but the more recent class of orally administered, type 2 diabetes treatments is putting some pressure on GLP-1 agonists as a whole. SGLT2 inhibitors reduce reabsorption of glucose in the kidneys, allowing it to exit the body in urine.

Again, Lilly is several steps behind the competition. In the U.S., type 2 diabetes patients unwilling or unable to inject GLP-1 agonists already have two SGLT2 options. Johnson & Johnson's pharmaceutical subsidiary Janssen began marketing Invokana in the U.S. last spring. Earlier this year the FDA approved Farxiga from AstraZeneca.

Lilly, in partnership with Boehringer Ingelheim, filed an NDA for SGLT2 treatment, empagliflozin, less than a week before the FDA approved Invokana. The application is still under review.

Final thoughts
During 2013 Novo Nordisk recorded more than $2 billion in Victoza sales, and the GLP-1 market is still growing. Express Scripts and other pharmacy benefit managers are clearly willing to replace preferred treatments for less expensive options that show similar benefit. Lilly has also proven it can compete on efficacy, and cut a deal when it needs to.

The non-insulin, type 2 diabetes treatment space is large and growing. Lilly will enter this market long after the competition, but it will be armed with some impressive clinical data. Dulaglutide and empagliflozin could go a long way to buoy sales figures as major patents expire.

What about the dividend?
One of the dirty secrets that few finance professionals will openly admit is the fact that dividend stocks as a group handily outperform their non-dividend paying brethren. The reasons for this are too numerous to list here, but you can rest assured that it's true. However, knowing this is only half the battle. The other half is identifying which dividend stocks in particular are the best. With this in mind, our top analysts put together a free list of nine high-yielding stocks that should be in every income investor's portfolio. To learn the identity of these stocks instantly and for free, all you have to do is click here now.

Cory Renauer has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information